CDC to soon launch NewLink/Merck Ebola vaccine study
This article was originally published in Scrip
Executive Summary
The Centers for Disease Control and Prevention (CDC) is nearly ready to launch its Phase II/III trial in Sierra Leone testing an experimental monovalent recombinant vesicular stomatitis virus (rVSV) Ebola vaccine from NewLink and its partner Merck.